Opioid Money Funding Psychedelic Research: The Loop Is Closing
Something remarkable is happening in state legislatures right now that I don’t think the legal community has fully processed yet.
Louisiana is advancing legislation that would use opioid settlement funds to create a Psychedelic-Assisted Therapy Initiative — funding clinical trials into psilocybin, ibogaine, and related compounds for addiction and mental health treatment.
Let that sit for a moment.
The settlement money extracted from the companies whose products drove one of the worst drug crises in American history is now being directed toward clinical research into a different class of compounds — ones that show early promise in treating the very addiction disorders the opioid crisis created.
Colorado is simultaneously funding ibogaine research and authorizing licensed treatment centers. Minnesota passed a cannabis bill that includes the first steps toward a therapeutic psilocybin program. The federal rescheduling of marijuana was blocked in a Congressional funding bill — so states are increasingly filling the vacuum.
Here is the legal complexity that nobody is talking about:
When a state becomes a clinical research sponsor using opioid settlement dollars, the federal regulatory framework doesn’t pause. IND requirements still apply. FDA oversight still applies. IRB standards still apply. Informed consent requirements still apply. State liability frameworks govern the clinical program — but federal law governs the drug.
And opioid settlement fund governance has its own layer: most settlement agreements include specific restrictions on how funds can be used, reporting requirements, and in many cases, court oversight. Whether psychedelic research falls within the authorized uses under those settlement agreements is a live legal question in almost every state that is now pointing those dollars at emerging therapies.
The worlds of litigation settlements, FDA regulatory law, and emerging therapies are now colliding — in state capitols, in IRB conference rooms, and in FDA pre-IND meetings. I find this to be one of the most interesting legal developments I have seen in a long time.
If you are a state attorney general’s office, a settlement fund trustee, a healthcare system, or a clinical research sponsor navigating this space, I’d welcome the conversation.
